Literature DB >> 19472089

Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates.

Sercan Aksoy, Omer Dizdar, Kadri Altundag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19472089     DOI： 10.1007/s12032-009-9236-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.

Authors:  Murat Dincer; Kadri Altundag; Hakan Harputluoglu; Sercan Aksoy; Mustafa Cengiz; Ibrahim Gullu
Journal:  Med Oncol       Date:  2008-01-15       Impact factor: 3.064

2.  Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis.

Authors:  M Bonomi; R Nortilli; A Molino; T Sava; A Santo; A Caldara; G L Cetto
Journal:  Med Oncol       Date:  2009-03-28       Impact factor: 3.064

3.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.